121 related articles for article (PubMed ID: 38679845)
1. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.
Bastard P; Cozic N; Brion R; Gaspar N; Piperno-Neumann S; Cordero C; Leculée-Thébaud E; Gomez-Mascard A; Rédini F; Marchais A; Ikonomova R; Cleirec M; Laurence V; Rigaud C; Abbas R; Verrecchia F; Brugières L; Minard-Colin V
Pediatr Blood Cancer; 2024 Jul; 71(7):e31029. PubMed ID: 38679845
[TBL] [Abstract][Full Text] [Related]
2. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
3. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
[TBL] [Abstract][Full Text] [Related]
4. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
6. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
8. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
Yang Q; Chen T; Yao Z; Zhang X
World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
11. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
12. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique.
Philip T; Iliescu C; Demaille MC; Pacquement H; Gentet JC; Krakowski I; Soler-Michel P; Thiesse P; Chauvin F; Blay JY; Brunat-Mentigny M
Ann Oncol; 1999 Sep; 10(9):1065-71. PubMed ID: 10572604
[TBL] [Abstract][Full Text] [Related]
15. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
Marec-Berard P; Laurence V; Occean BV; Ray-Coquard I; Linassier C; Corradini N; Collard O; Chaigneau L; Cupissol D; Kerbrat P; Saada-Bouzid E; Delcambre C; Gouin F; Guillemet C; Jimenez M; Lervat C; Gaspar N; Le Deley MC; Brugieres L; Piperno-Neumann S
J Adolesc Young Adult Oncol; 2020 Apr; 9(2):172-182. PubMed ID: 31702419
[No Abstract] [Full Text] [Related]
17. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S; Bielack SS; Whelan J; Bernstein M; Hogendoorn P; Krailo MD; Gorlick R; Janeway KA; Ingleby FC; Anninga J; Antal I; Arndt C; Brown KLB; Butterfass-Bahloul T; Calaminus G; Capra M; Dhooge C; Eriksson M; Flanagan AM; Friedel G; Gebhardt MC; Gelderblom H; Goldsby R; Grier HE; Grimer R; Hawkins DS; Hecker-Nolting S; Sundby Hall K; Isakoff MS; Jovic G; Kühne T; Kager L; von Kalle T; Kabickova E; Lang S; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Mayer-Steinacker R; Meyers PA; Nagarajan R; Randall RL; Reichardt P; Renard M; Rechnitzer C; Schwartz CL; Strauss S; Teot L; Timmermann B; Sydes MR; Marina N
Eur J Cancer; 2019 Mar; 109():36-50. PubMed ID: 30685685
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
